ALLR supply chain intelligence for Allarity Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| STREETERVILLE-CAPITAL | STREETERVILLE-CAPITAL | 90% | On March 6, 2026, Allarity Therapeutics, Inc. (the “Company”) announced the closing of a $20 million non-convertible debt financing with Streeterville Capital. |
| TUMIN-STONE-CAPITAL-LLC | TUMIN-STONE-CAPITAL-LLC | 80% | the Common Stock Purchase Agreement with Tumin Stone Capital LLC dated January 28, 2026, so long as such agreement is not amended, modified or replaced after the date hereof |
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from ALLR graph: Reciprocal relationship from AZN graph: Reciprocal relationship from ALLR graph: ting the need for us to invest in our… |
| AZN | AstraZeneca PLC | 72% | ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the development of our investigational produ… |
| BMY | Bristol-Myers Squibb Company | 72% | ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the development of our investigational produ… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from ALLR graph: ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to … |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from ALLR graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from ALLR graph: Reciprocal relationship from BMYM… |
| BMYMP | Bristol-Myers Squibb Co | 72% | ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the development of our investigational produ… |
| KURA | Kura Oncology, Inc. | 72% | Reciprocal relationship from KURA graph: Reciprocal relationship from ALLR graph: Reciprocal relationship from KURA graph: Reciprocal relationship from ALLR graph: Reciprocal relationship from KURA g… |
| KURA | Kura Oncology, Inc. | 72% | ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the development of our investigational produ… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the development of our investigational produ… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from ALLR graph: ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to… |
| SNYNF | Sanofi | 72% | ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the development of our investigational produ… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from ALLR graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ALLR graph: ting the need for us to invest in… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from ALLR graph: ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to … |
| AZN | AstraZeneca PLC | 72% | ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the development of our investigational produ… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from ALLR graph: Reciprocal relationship from BMY graph: Reciprocal relationship from ALLR graph: Reciprocal relationship from BMY grap… |
| BMY | Bristol-Myers Squibb Company | 72% | ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the development of our investigational produ… |
| BMYMP | Bristol-Myers Squibb Co | 72% | ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the development of our investigational produ… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from ALLR graph: ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us t… |
| KURA | Kura Oncology, Inc. | 72% | Reciprocal relationship from KURA graph: Reciprocal relationship from ALLR graph: ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to… |
| KURA | Kura Oncology, Inc. | 72% | ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the development of our investigational produ… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the development of our investigational produ… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from ALLR graph: ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from ALLR graph: ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us t… |
| SNYNF | Sanofi | 72% | ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the development of our investigational produ… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| ALLR-DEBT | Debt stack $1.4M | 90% | Market cache reports total debt of $1.4M. |
| ALLR-DEBT-7686 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2025-09-30. |
| ALLR-DEBT-7685 | Warrants outstanding: 71734 | 90% | xbrl warrant detail from xbrl 2024-12-31. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| BMY | Bristol-Myers Squibb Company | 100.00 | 1 | ['customer', 'supplier'] |
| KURA | Kura Oncology, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| AZN | AstraZeneca PLC | 100.00 | 1 | ['customer', 'supplier'] |
| BMYMP | Bristol-Myers Squibb Co | 100.00 | 1 | ['customer', 'supplier'] |
| SNYNF | Sanofi | 100.00 | 1 | ['customer', 'supplier'] |
| ANL | Adlai Nortye Ltd. | 50.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 50.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 50.00 | 2 | |
| EMMA | Emmaus Life Sciences, Inc. | 50.00 | 2 | |
| DEO | Diageo plc | 50.00 | 2 | |
| CRVS | Corvus Pharmaceuticals, Inc. | 50.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 50.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 50.00 | 2 | |
| FATE | Fate Therapeutics, Inc. | 50.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 50.00 | 2 | |
| CCCC | C4 Therapeutics, Inc. | 50.00 | 2 | |
| RXRX | Recursion Pharmaceuticals, Inc. | 50.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 50.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 50.00 | 2 |